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Higher Prevalence of Unrecognized Kidney Disease at High Altitude 
 
Abstract  
Background High altitude renal syndrome has been described in populations with excessive erythrocytosis. We 
evaluated whether high altitude (HA) dwellers might be at increased risk for kidney disease.    
Methods: We performed a cross-sectional study to investigate differences in prevalence of kidney function and 
metabolic syndrome in healthy subjects living at HA and sea level (SL) without any known history of hypertension, 
diabetes or chronic kidney disease.  
Results. We examined 293 subjects, age 40 to 60 years, 125 from SL (154 m) and 168 HA (3640 m). HA subjects 
had higher serum creatinine, lower estimated glomerular function rate (eGFR) (69.5 ± 15.2 vs 102.1 ± 17.8 
ml/min/1.73 m2, p <0.0001), with more proteinuria and higher hemoglobin concentrations compared to SL subjects. 
HA subjects had a lower prevalence of metabolic. Hemoglobin concentrations correlated inversely with eGFR in 
women and men (p = 0.001 and p= 0.03, respectively) among subjects living at HA.  Using logistic regression 
analysis to compare subjects with eGFR < 90 versus > 90 ml/min/1.73m2, a lower eGFR was associated with gender 
(women) (OR adjusted: 5.65; 95% CI : 2.43-13.13, p = 0.001), high altitude (OR adjusted: 14.78, 95% CI : 6.46-
33.79; p = 0.001), hemoglobin (OR adjusted: 1.68; 95% CI : 1.16-2.43; p = 0.001) and uric acid (OR adjusted: 1.93; 
95% CI : 1.36-2.72; p = 0.001).   
Conclusions: Subjects living at high altitude who are considered healthy have worse kidney function, a higher 
prevalence of proteinuria and a lower prevalence of metabolic syndrome compared to people living at SL.   
 












































































Chronic kidney disease (CKD) has many known causes, including diabetes, hypertension, glomerulonephritis and 
polycystic kidney disease. However, CKD may be caused by other mechanisms. We have hypothesized that living 
chronically at high altitude (HA) may be a risk factor for CKD related to the chronic exposure to hypoxia due to low 
ambient oxygen tension [1,2]. 
Recently we have reported that  subjects  living at HA are at risk for high altitude renal syndrome “HARS”, a 
condition characterized by erythrocytosis, microalbuminuria, hypertension and hyperuricemia [3,4]. This is 
especially observed in subjects suffering from chronic mountain sickness (CMS), a form of altitude maladaptation 
characterized by excessive erythrocytosis (hematocrit > 65 %) and greater arterial hypoxemia (SaO2% < 85) [5]. 
While the pathogenesis of HARS is not fully understood, it  may relate to  glomerular hyperfiltration associated with 
polycythemia [6], or the effects of hyperuricemia on glomerular hemodynamics and tubular function [7,8].  
Given these issues, we compared two similar ethnic populations: one living at sea level (Lima, Peru, altitude 154 m) 
versus one at high altitude (La Paz, Bolivia, altitude 3,640-4,500 m). We specifically wanted to compare ‘healthy’ 
populations who had no known  hypertension, diabetes or  CKD. Our hypothesis was that, even within an apparently 
healthy population and those without CMS, subjects chronically living at high altitude would show more evidence 
for kidney dysfunction.  
 
Material and Methods  
Study Design.  
This was a cross–sectional study that evaluated subjects from La Paz, a city in Bolivia located at an altitude between 
3,640 – 4,500 meters and Lima, a city in Peru, which is located at 154 meters above sea level. Both cities are 








































































We performed screening campaigns in the community of both cities, and the subjects were selected by convenience 
sampling if they fulfilled criteria of selection in the first interview. After the results of laboratory testing were 
obtained, additional subjects could be excluded based on fasting blood glucose levels of >125 mg/dl (n=19) and/or 
significantly elevated serum creatinine (> 1.4 mg/dl, n=8).  The remaining 293 participants were aged 40 to 60 
years, with no prior known history of hypertension, diabetes, chronic kidney disease, CMS or other chronic medical 
conditions. Informed consent was obtained from all individual participants included in the study.  The exclusion 
criteria included a history of any systemic disease, long-term use of medications and incomplete information of the 
subject's condition or laboratory data. The protocol followed the principles of the Declaration of Helsinki. The study 
was approved by the ethics committee of the Hospital Nacional Arzobispo Loayza in Lima, Peru.   
 
Evaluation   
A detailed history was obtained from all including past medical history, family history of diabetes and kidney 
disease, as well as life style habits (alcohol and tobacco use and physical activity). We used the International Society 
of Nephrology form: “Program for Detection and Management of CKD, Hypertension, Diabetes and Cardiovascular 
Disease in Developing Countries”, which was adapted to the needs of the study [9].  Physical examination included 
weight, height (after removal of shoes and heavy clothing), waist circumference (measured at the midpoint between 
the bottom edge of the last rib and the iliac crest taking as a reference the mid-axillary line and taken at the end of 
expiration) and hip circumference (measured using the maximum circumference at the level of the buttocks). Body 
mass index (BMI) and waist-hip ratio (WHR) were calculated. Blood pressure was measured following 
recommended procedures after sitting for 15 minutes [10], after which three readings were recorded at intervals of 
three minutes using a calibrated automatic blood pressure monitor OMROM, model HEM-705CP. Venous blood 
was obtained after 12 hours of fasting for total cholesterol, low density lipoprotein (LDL), high density lipoprotein 
(HDL), triglycerides, glucose, uric acid, hemoglobin, hematocrit, and creatinine with enzymatic methods. The data 
were processed in a computer model: STAT FAX 1935 PLUS, Roche Cobas C501. All coefficients of variation for 
original measurements were < 10%. Morning spot urine samples were evaluated for proteinuria and hematuria with 






































































Overweight was defined as BMI between 25-30 kg/m2 and obesity as BMI > 30 kg/m2. Abdominal obesity was 
defined as WHR > 0.9 in men and > 0.85 in women. Estimated glomerular filtration rate (eGFR) was calculated 
using the Modification of Diet in Renal Disease (MDRD) four variables equation. Kidney Disease (KD) stages were 
classified according to Kidney Disease Outcomes Quality Initiative (KDOQI) [11]. Hematuria and proteinuria were 
defined as 1+ or greater on a dipstick test.  The diagnosis of metabolic syndrome was based on the presence of 3 of 
the 5 following criteria: waist circumference > 94 cm in men and > 88 cm in women, triglyceride ≥ 150 mg/dl, high 
density  lipoprotein  HDL < 40 mg/dl in men and < 50 mg/dl in women, systolic blood pressure ≥ 130 mmHg and/or 
DBP ≥ 85 mmHg, fasting blood glucose ≥ 100 mg/dl [12]. The cardiovascular risk was calculated using the 
Framingham risk score [13]. This score addresses the following variables: age, sex, systolic blood pressure treated 
(medication and lifestyle changes) and untreated, BMI, smoking and diabetes. The consumption of alcohol and 
tobacco, and physical activity was recorded as present or absent.  
Sample Size. We calculated a necessary sample size of 318 subjects to have 80 % power and a confidence interval 
of 95 % based on chronic KD prevalence of 10 % SL [14] and 19% for HA [15]. The sample calculation was 
obtained from the statistical package Stata v12 using the formula for comparison of two separate proportions. 
Statistical analysis. An exploratory data analysis was done by obtaining measurements of central tendency such as: 
mean, standard deviation, median, minimum and maximum values for quantitative variables, and frequencies and 
percentages for qualitative variables. Before comparing means or medians, the distribution of the quantitative 
variables was evaluated using the Shapiro-Wilk test and the homogeneity of variance with Bartlett's test. To assess 
association between two qualitative variables in the bivariate analysis, Chi Square test or Fisher exact test were used 
respectively depending on the expected frequency number of more than 5 or not. Student’s t-test was used for 
comparing two arithmetic means (when the distribution of the variable had a normal distribution), two-sample 
Wilcoxon rank-sum (Mann-Whitney) test was used for independent samples when the distribution of the variable 
was not normal. Multiple logistic regression was used to assess factors associated with renal disease (defined as 
CKD stage II, or an eGFR < 90 ml/min/1.73 m2). The level of statistical significance considered was 0.05, for a two-






































































Baseline characteristics of study subjects. Of the 320 subjects selected, we excluded subjects with fasting glucose 
concentrations greater than 126 mg/dl who did not know whether they were diabetic (n = 19), and those with 
creatinine greater than 1.4 mg/dl (n = 8). Thus, 293 subjects were included in the final analysis (representing 92 % 
of the sample). Of these 125 were living at SL and 168 at HA. There were 145 men (65 SL, 80 HA) and 148 women 
(60 SL, 88 HA). 
Baseline characteristics of subjects living at SL and HA. There were no significant differences in age or sex 
between the two groups.  Compared to SL subjects, kidney function in the HA subjects was characterized by higher 
serum creatinine (1.05 ± 0.14 vs 0.77 ± 0.16 mg/dl, p < 0.0001), lower eGFR (69.5 ± 15.2 vs 102.2 ± 17.8 
ml/min/1.73m2, p < 0.0001), higher percentage of patients with eGFR < 60 ml/min/1.73 m2 (28.0 % vs 0 %, p < 
0.001) and proteinuria (10.7 % vs 3.2%, p = 0.03).  
HA subjects had higher hemoglobin concentrations (15.4 ± 1.4 vs 13.9 ± 1.2 g/dl, p < 0.0001), HDL level (48.9 ± 
12.0 vs 44.9 ± 10.9 mg/dl, p < 0.002) and fasting triglycerides level (159.9 ± 99.6 vs 123.4 ± 55.7 mg/dl, p < 0.001). 
In contrast, high altitude dwellers had  less alcohol intake (40.5 % vs. 56.8 %, p < 0.05), lower  systolic blood 
pressure (114.3 ± 15.9 vs 129.7 ± 17.2 mmHg, p < 0.0001) and diastolic blood pressure  (71.5 ±  8.5 vs 76.3 ± 10.0 
mm Hg, p < 0.0001), as well as lower weight (69.2 ± 10.9 vs 73.2 ± 14.2, p = 0.03), BMI (26.2 ± 3.6  vs 28.9 ± 4.3 
kg/m2, p < 0.0001), waist-hip ratio (0.96 ± 0.04 vs 0.92 ± 0.07, p < 0.0001), fasting serum glucose level (74.2 ± 8.4  
vs 93.1 ± 10.9 mg/dl, p < 0.0001), LDL level (126.2 ± 41.3 vs 144.9 ± 33.4, p < 0.0001), prevalence of metabolic 
syndrome (27.4 % vs 49.6 %, p < 0.0001) and  Framingham risk score (0.91 ± 1.15 vs 2.13 ± 2.65, p < 0.001 (Table 
1). 
Values of hemoglobin, kidney function, metabolic syndrome and Framingham risk score in men and women living 
at SL and HA are shown in Table 2.     
Multivariable logistic regression was used to compare subjects with evidence for stage 2 CKD or worse (eGFR 90 
ml/min/1.73m2) versus those with normal renal function (defined as eGFR > 90 ml/min/1.73m2). After adjusting for 
age, sex, place of residence, hemoglobin, triglycerides, metabolic syndrome, uric acid, a lower eGFR was associated 




































































95% CI : 6.46-33.79; p = 0.001), having a higher hemoglobin (OR adjusted: 1.68; 95% CI: 1.16-2.43; p = 0.001) and 
for each unit of increase in uric acid (OR adjusted: 1.93; 95% CI: 1.36-2.72; p = 0.001), Table 3 
   
Relationship between eGFR and hemoglobin in women and men.  
In HA women and men, hemoglobin correlated inversely with eGFR (p = 0.001 and p = 0.03, respectively; r = - 0.2, 
p = 0.01), but no significant correlation was observed in women or men living at SL (Figures 1 and 2).   
 
Discussion  
In this cross-sectional study of 293 healthy ethnically similar participants from two cities of different altitude in 
South America, we found that individuals living at high altitude had significantly worse renal function than those 
living near sea level, amounting to a mean difference of eGFR of 30 percent. The worse kidney function and greater 
proteinuria observed at higher altitude occurred despite similar age and lower prevalence of metabolic syndrome 
compared to people living near sea level.  
The prevalence of eGFR < 60 ml/min/1.73 m2 and proteinuria was 28.0 % and 10.7 % respectively, among subjects 
living at HA and this was observed after excluding subjects with hypertension, diabetes, or known CKD. This 
prevalence is higher than values reported in Tibet, which are 2.1% for CKD and 2.4% for proteinuria [15]. One 
possible explanation is that Tibetans have been living at high altitude for many more generations than any groups in 
the Andes [16] and are therefore better adapted to the high altitude hypoxic environment, as evidenced by their 
higher arterial oxygen saturation and lesser hemoglobin concentration.   
Potential mechanisms for the worse renal function at HA could be chronic hypoxia, leading to erythrocytosis. 
Increased red cell volume leads to reduced renal plasma flow (RPF) which eventually results in higher filtration 
fraction (FF) as glomerular filtration rate is preserved [6,17]. These characteristics resemble a model of chronic 
hyperfiltration, with its known consequences of glomerular damage and proteinuria [18]. The population at HA in 
our study did not have excessive erythrocytosis typical of CMS (hematocrit > 65%), nonetheless increased 




































































The renal medulla is hypoxic with a range of PO2 between 10-20 mmHg [2,19] and is highly susceptible to injury by 
hypoxia [20].  Medullary hypoxia is likely more severe among high altitude dwellers given their lower arterial 
oxygen saturation and no off-setting higher renal blood flow (2), thus further increasing the risk of renal injury.  
Indeed, hypoxia is a well-known risk factor for progressive CKD in various experimental animal models [19]. 
Similarly, subjects with kidney disease also have higher serum uric acid concentrations, which are known to be 
elevated in hypoxic conditions. While uric acid can function as an antioxidant [21], it can also stimulate oxidative 
stress in a variety of cell types, and can also cause endothelial dysfunction, and systemic and glomerular 
hypertension [22] thereby predisposing to the risk of CKD. We also found that HA subjects tended to have higher 
serum uric acid concentrations, although this was not statistically significantly different compared to the SL group. 
This may be due to the higher frequency of the metabolic syndrome in the SL group, which is also associated with 
hyperuricemia.  
 
We also found a lower frequency of metabolic syndrome at HA. While it may be argued that the higher frequency of 
metabolic syndrome among SL dwellers might reflect different dietary or economic factors, the HA subjects were 
also urban residents in a large city (La Paz) with a comparable socioeconomic environment. Other factors may also 
be important for example, physical activity was more common among men but not women at HA, and might explain 
differences in weight. The metabolic responses to chronic hypoxia may also have protective effects on the 
development of the metabolic syndrome. HA residents are known to have lower serum glucose concentrations than 
inhabitants at SL [23]. Consistent with this observation, a lower incidence of diabetes has been observed at HA [24].  
A lower fasting serum glucose concentration was observed in our study and contributes to a lower incidence of the 
metabolic syndrome in the population at HA. Furthermore, living at HA is also associated with higher HDL 
concentrations [25]. Not all studies, however, have found that the metabolic syndrome is lower at HA. A prior study 
from Peru found no difference in the metabolic syndrome between high altitude and sea level dwellers (22.2 % vs. 
16.9 % respectively; p = 0.28) [26]. In another study, the metabolic syndrome was extremely high (60 %) among 
individuals living at high altitude with excessive erythrocytosis (mean age 61 yr) compared to a prevalence of 35 % 
among high altitude residents without erythrocytosis (mean age 55 yr) [27].  Another study of the Peruvian 
population also reported that subjects living at higher altitude had a metabolically healthier profile than those living 




































































The Framingham risk score is a quantitative method that estimates the likelihood of coronary heart disease over a 
period of time, and has been validated in various ethnic groups [29]. The population at HA (both men and women) 
had a lower Framingham score compared to the population living at sea level. The lower score in HA residents was 
primarily due to the higher HDL concentrations, lower prevalence of smoking, and lower blood pressure. Among 
women, the variables of age, cholesterol, HDL and smoking were similar, so that the lower Framingham score at 
HA was primarily due to a lower blood pressure. A study in Tibet reported a lower Framingham risk score than what 
we found in our Andean population: 16. 3% for men and 0.6 % for women [30]. 
Our study has several limitations. First, it was a study of healthy individuals, and we did exclude subjects with 
known hypertension, diabetes or CKD.  Therefore, it is not a study of overall prevalence of CKD.  However, the 
striking finding that eGFR was 30 percent lower in the presumably healthy population at HA remains remarkable. 
Second, we did not assess for microalbuminuria. We also excluded subjects with hypertension, which may be part of 
the high altitude renal phenotype.  However, by excluding subjects with hypertension we could also remove the 
possibility that the kidney disease was secondary to hypertension alone. A final limitation is that we failed to gather 
information on dietary history and measured the laboratory values only once. Nevertheless, the strength of the study 
is the robust differences identified in prevalence of kidney disease and metabolic syndrome.  
In conclusion, apparently healthy subjects living at high altitude had a remarkably higher frequency of kidney 
disease and proteinuria independent of a history of hypertension or diabetes. This provides some of the strongest 
evidence to date that long-term living at high altitude carries an increased risk for kidney disease. The characteristics 
of kidney disease observed at high altitude may be a new form of CKD that might be mediated by chronic hypoxia 
and its effects. Given that there are more than 140 million people worldwide living at high altitude, further studies to 



















































































Ethical approval:  
“All procedures performed in studies involving human participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments 
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 Mean ± SD                    95 %CI  
High altitude 
(n=168) 
Mean ± SD                  95%CI  
p* 
Age (years) 1 50.79 ± 6.86               49.57 - 52.00 50.58  ± 5.79         49.70 - 51.46 0.679 
Sex (men / women)4,a 65/60                          0.39 – 0.56 80/88                      0.44 – 0.60 0.458 
Alcohol 5,a 71 (56.8%)                 0.47 – 0.65 68 (40.5%)              0.32 – 0.47  0.0001* 
Smoking 5,a 21 (16.8%)                0.10 – 0.23 17 (10.1%)              0.55 – 0.14  0.114 
Physical Activity 5,a 51 (40.8%)                0.32 – 0.49 73 (43.4%)              0.35 – 0.51 0.649 
Systolic blood pressure 
(mmHg) 3 
129.71 ±17.22          126.66 – 132.76 114.34 ± 15.90       111.92 – 116.76 0.0001* 
Diastolic blood pressure 
(mmHg) 3 
76.37 ± 10.04           74.59 – 78.15 71.51 ± 8.50           70.22 – 72.81 0.0001* 
Pulse (beats per min) 1 69.60 ±10.20            67.79 – 71.40 73.51 ± 3.85           72.93 – 74.10 0.0001* 
Weight (kg) 3 73.16 ± 14.16          70.65 – 75.67 69.24 ± 10.95        67.57 – 70.91 0.030 
Height (cm) 3 158.7 ± 9.57            157.00 – 160.39 162.48 ± 6.70       167.46 – 163.50 0.0001* 
Body mass index(kg/m2) 3 28.90 ± 4.29           28.14 – 28.66 26.18 ± 3.61         25.63 – 26.74 0.0001* 
Waist circumference (cm) 2 102.84 ± 9.28         101-20 – 104.49        101.04 ± 10.47     99.44 – 102.63 0.283 
Hip circumference (cm)2 99.58 ± 8.94          98.00 – 101.16 93.90 ± 13.82       91.79 – 96.01 0.0001* 
Waist-hip ratio 2 0.96 ± 0.04            0.96 – 0.97 0.92 ± 0.07           0.91 – 0.93 0.0001* 
Hemoglobin (g/dl) 1 13.91 ± 1.22         13.69 – 14.12 15.43 ± 1.36         15.23 – 15.64 0.0001* 
Glucose (mg/dl) 1 93.07 ± 10.94       91.13 – 95.01 74.23 ± 8.36        75.95 – 75.50 0.0001* 
Creatinine (mg/dl) 3 0.77 ± 0.16           0.74 – 0.80 1.05 ± 0.14          1.03 – 1.08 0.0001* 
eGRF (ml/min/1.73m2) 1 102.15 ± 17.82     98.99 – 105.31 69.52 ± 15.18      67.21 – 71.84 0.0001* 
eGRF level (ml/min/1.73m2) 4,a 
    > 90 
 60 - 89 











  Hemoglobin (positive) 










Total cholesterol (mg/dl) 1 216.90 ± 41.63    209.53 – 224.27 209.32 ± 54.13   201.08 – 217.57 0.08 
Low density lipoprotein 
(mg/dl)  1 
144.86 ± 33.40   138.94 – 150.77 126.22 ± 41.28   119.93 – 132.50 0.0001* 
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High density lipoprotein 
(mg/dl) 1 
44.92 ± 10.90       42.99 – 46.85 48.92 ± 11.97         47.10 – 50.75 0.002* 
Triglycerides (mg/dl)  1 123.42 ± 55.68    113.56 – 133.28 159.89 ± 99.58    144.72 – 175.06 0.001* 
Uric acid (mg/dl)  1 4.92 ± 1.18          4.71 – 5.13 5.11 ± 1.43           4.89 – 5.33 0.379 
Metabolic syndrome 4,a 62 (49.6%)          0.40 – 0.58 46 (27.38%)        0.20 – 0.34 0.0001* 
Framingham risk score 1 2.13 ± 2.65          1.66 – 2.60 0.91 ± 1.15         0.73 – 1.08 0.001* 
(Mean ± Standard Deviation) 
(N° and % ± Standard Error) a 
1 Mann–Whitney test  
2 Student's t-test with unequal variances  
3 Student's t-test with equal variances 
4 Chi-square test 
5 Fisher's exact test  






















Table 2 Characteristics of hemoglobin, kidney function, metabolic syndrome and     





n = 65 
High 
altitude 
n = 80 
p Sea level 
n = 60 
High 
altitude 
n = 88 
p 
Hemoglobin (g/dl) 1 
 
14.6 ± 0.8 15.5 ± 0.9 0.001 13.1 ± 1.1 15.3 ±1.6 0.001 
Creatinine (mg/dl) 3   
0.88 ± 0.14 1.05 ± 0.14 0.001 0.64 ± 0.08 1.05 ± 0.14 0.001 
eGRF (ml/min/1.73m2) 1 99.2 ± 18.8 80.4 ± 12.6 0.001 105.3 ±16.2 59.7 ± 9.6 0.001 
eGRF level 
(ml/min/1.73m2) 4 
  > 90 
 60 - 89 


















Metabolic syndrome 4 32 (49.2%) 25 (31.3%) 0.04 30 (50%) 21 (23.9%) 0.001 
Framingham risk score 1 3.22 ± 3.06 1.49 ± 1.37 0.001 0.95 ±1.36 0.38 ± 0.50 0.001 
(Mean ± standard deviation; n° and %) 
1 Mann–Whitney test  
2 Student's t-test with unequal variances  
3  Student's t-test with equal variances 








Table 3: Unadjusted and Multivariable-adjusted Odds of eGFR < 90 ml/min/1.73m2 






Age (years) 1.00 0.97-1.04 0.64 1.02 0.97-1.08 0.34 
Sex: Female 1.58 0.99-2.53 0.05 5.65 2.43-13.13 0.001 
High altitude 20.86 11.39-38.21 0.001 14.78 6.46-33.79 0.001 
Hemoglobin (g/dl) 2.22 1.76-2.80 0.001 1.68 1.16-2.43 0.001 
Triglycerides (mg/dl) 1.00 1.00-1.00 0.001 1.00 0.99-1.00 0.51 
Metabolic syndrome 0.54 0.33-0.87 0.01 0.48 0.21-1.11 0.08 
Uric acid (mg/dl) 1.46 1.20-1.79 0.01 1.93 1.36-2.72 0.001 
Adjusted for age, sex, high altitude, hemoglobin, triglycerides, metabolic syndrome, uric acid. 
P-values calculated using logistic regression.  





Figure 1: Estimated glomerular filtration rate versus hemoglobin level at different altitude in 
women. 
Box-plot diagram of the relationship between estimated glomerular filtration rate (eGFR) and hemoglobin 
level in women, at high altitude hemoglobin increased significantly with decreasing eGFR levels (p = 














Figure 2: Estimated glomerular filtration rate versus hemoglobin level at different altitude in men 
Box-plot diagram of the relationship between estimated glomerular filtration rate (eGFR) and hemoglobin 
level in men. at high altitude hemoglobin increased significantly with decreasing eGFR levels (p = 0.03: r 
= - 0.2, p = 0.01), but no in men living at sea level. Statistical: Kruskal-Wallis, Spearman. 
 
 
 
 
 
 
 
 
 
 
